US cancer survival has improved, but gains remain uneven


Epidemiologists point to advances in lung-cancer treatment and better dosing schedules for childhood leukaemia as two different routes to progress.
Five-year survival after a cancer diagnosis in the United States has risen from 49% in the late 1970s to 71%. But that overall gain covers sharply different outcomes: the later rate for lung cancer was 29%, compared with 90% for lymphoid leukaemia among children and adolescents up to age 19.
The figures come from the American Association for Cancer Research’s (AACR) Cancer Progress Report 2026, released in September and described by Nature on 5 October 2026. They compare survival for at least five years after diagnosis.
| Cancer group | Earlier survival | Later survival |
|---|---|---|
| Cancer overall | 49% — late 1970s | 71% |
| Lung cancer | 13% — diagnoses in 1975–1979 | 29% — diagnoses in 2016–2022 |
| Lymphoid leukaemia — children and adolescents up to age 19 | 57% | 90% |
Rebecca Siegel, a cancer epidemiologist—a researcher who studies cancer patterns in populations—at the American Cancer Society in Atlanta, Georgia, calls the lung-cancer gains particularly striking. Five-year survival more than doubled between the two diagnosis periods, although the later rate remained below one-third.
Nature’s discussion links that improvement to better surgical techniques and radiation treatments, alongside new medicines. Some medicines help the immune system attack tumours. Others target cancer cells with particular mutations, or changes in their genetic material.
Michel Coleman, an epidemiologist at the London School of Hygiene and Tropical Medicine, says global statistics broadly show the same trend towards greater survival. That observation does not mean every country has achieved the US rates.
For childhood lymphoid leukaemia, Siegel describes a different route to improvement. The rise from 57% to 90% did not come from discovering a transformative therapy, she says. Instead, researchers worked together to carefully adjust the doses and timing of treatments that were already available.
The distinction matters: progress can involve improving how existing therapies are given, not only developing new medicines. These survival comparisons do not, on their own, establish how much any individual treatment contributed or show whether cancer death rates fell.

A 1976 crystal-lattice model revealed nested bands and gaps. A later connection to the quantum Hall effect gave those gaps an electrical meaning.
4 min

Unusual chemistry around white dwarf HS 0209+0832 may trace a world made from the star’s expelled material. The planet and its proposed origin remain unconfirmed.

Unusual chemistry and a roughly 4.4-day brightness cycle around a white dwarf could indicate a gas giant formed from the star’s expelled material. The planet remains unconfirmed.
3 min
3 min